Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setanaxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 known ✓ | Q9NPH5 | 20/20 | 1.00 |
| ▸ | NOX1 known ✓ | Q9Y5S8 | 5/20 | 1.00 |
| ▸ | CYBB | P04839 | 5/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setanaxib SCHEMBL29362127 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL1302603 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612593 | 0.87 | NOX4 (0.77) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612522 | 0.86 | NOX4 (0.75) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302255 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5 | |
| SCHEMBL16612222 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29523003 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931735 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302943 | 0.83 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931788 | 0.82 | NOX4 (0.69) | NOX4CYBBNOX1NOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703747-B1 | USE OF A NOX4 OR NOX4/1 INHIBITOR IN COMBINATION WITH AN IMMUNOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-09-03 | — | — | EP | claimed |
| US-12377117-B2 | Hyaluronic acid nanoparticles comprising NADPH oxidases inhibitors and uses in treating cancer | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | claimed |
| CN-119212698-A | NOX inhibitors for the treatment of Albert syndrome | 瑞士商卡利迪塔斯疗法瑞士股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| CN-119212698-A | NOX inhibitors for the treatment of Albert syndrome | 瑞士商卡利迪塔斯疗法瑞士股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-10-31 | — | — | US | disclosed |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-4355915-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | Genfit (FR) | 2024-04-24 | — | — | EP | disclosed |
| CN-111065748-B | Non-invasive diagnosis of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and/or liver fibrosis | 基恩菲特公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4299077-A2 | SKIN ENHANCING COMPOSITIONS AND METHODS | Sytheon Limited (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4157270-A1 | NEUROKININ (NK)-1 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF PULMONARY FIBROSIS CONDITIONS PROMOTED BY MECHANICAL INJURY TO THE LUNGS | NeRRe Therapeutics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| EP-4158353-A1 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF ESSENTIAL PRIMARY HYPERTENSION | Universiteit Maastricht (NL) | 2023-04-05 | — | — | EP | disclosed |
| CN-115697332-A | Neurokinin (NK) -1 receptor antagonists for the treatment of pulmonary fibrotic conditions promoted by mechanical injury of the lung | 尼尔医疗有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-110536682-B | Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents | 基恩菲特公司 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022263565-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2022-12-22 | — | — | WO | disclosed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3946297-A1 | HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASES INHIBITORS AND USES IN TREATING CANCER | Emory University (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | NOX1, NOX5, NOX3 | NOX4 5/4885NOX1 1/4885CYBB 6/4885 |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | NOX4 5/4885NOX1 1/4885CYBB 6/4885 |
| US-12377117-B2 | Hyaluronic acid nanoparticles comprising NADPH oxidases inhibitors and uses in treating cancer | NOX1, NOXO1, CYBB | NOX4 5/4885NOX1 1/4885CYBB 3/4885 |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | NOX4 1837/4885NOX1 2565/4885CYBB 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.